Mode
Text Size
Log in / Sign up

Influenza A(H3N2)

Part of Influenza

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Influenza A(H3N2)

17 trials tracked for Influenza A(H3N2): 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 136 citations.

17Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 6 Phase 1 2 Other / NA 5
  1. Phase 3 Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza Completed · 136 cited
  2. Phase 3 Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A Completed · 112 cited
  3. Phase 4 Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations Completed
  4. Phase 4 Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents Completed
  5. Phase 2 Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza Completed
  6. Phase 2 Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A Completed
Show 11 more trials
  1. Phase 2 A Study to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model Completed
  2. Phase 2 A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults Completed
  3. Phase 2 Study Examining PrEP-001 in Healthy Subjects Completed
  4. Phase 2 Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A Completed
  5. Phase 1 Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines Completed
  6. Phase 1 CC-42344 Safety Study in Healthy Participants Completed
  7. N/A Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain Completed
  8. N/A SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings Completed
  9. N/A Collection and Testing of Respiratory Samples Completed
  10. N/A Assessment of Wearable Sensors During Experimental Human Influenza Infection (Sigma Plus) Completed
  11. N/A MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Influenza A(H3N2): what the trials found

The Influenza Fluzone vaccine is established for use in the management of Influenza A(H3N2) 1. Additionally, LAIV has been evaluated as an intervention for this condition 4.

Clinical trials evaluating passive immunity treatments, including Intravenous hyperimmune immunoglobulin (IVIG) 5 and high-titer anti-influenza plasma 6, did not show statistically significant differences in clinical status categories at Day 1, Day 2, or Day 7 compared to control groups.

Recent results — preliminary, needs further review

  • CC-42344 is currently being evaluated in a Phase 1 trial 2.
  • A study of the Influenza A H3N2 virus dose arm 1 reported various peak symptom scores, including Peak Total Symptoms Diary Card Scores ranging from 2.75 to 5.40 3.

For the clinician treating this condition

  • Influenza Fluzone and LAIV are established interventions for Influenza A(H3N2) [1, 4].
  • Passive immunity treatments such as IVIG and high-titer anti-influenza plasma did not demonstrate statistically significant improvements in clinical status over the first week of treatment [5, 6].

AI synthesis of 6 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Influenza

Related studies from across the Influenza family.

Bangga extracts show antibacterial, anti-inflammatory, antiviral, and antitumor activity in preclinical synthesis
Drug Pipeline Sys. Review
Bangga extracts show antibacterial, anti-inflammatory, antiviral, and antitumor activity in preclinical synthesis Extracts of Aconitum tanguticum Show Potential for Several Conditions
This systematic review synthesizes preclinical evidence on Aconitum tanguticum (Bangga), reporting antibacterial, anti-inflammatory, antivir…
Research into Aconitum tanguticum extracts shows potential antibacterial, antiviral, and anti-inflammatory properties for various inflammato…
Opt-out nudge reduces number of unvaccinated medical residents by 81% for influenza
Primary Care & Family Medicine RCT
Opt-out nudge reduces number of unvaccinated medical residents by 81% for influenza Opt-out Nudges Increase Influenza Vaccination Rates Among Medical Residents
This randomized controlled trial of 260 medical residents in France found that an opt-out nudge significantly increased vaccination rates. T…
A simple opt-out nudge significantly increased flu vaccination rates among medical residents while maintaining their sense of personal choic…
Seasonal influenza vaccine effectiveness increased against A(H3N2) and B strains in post-pandemic period
Pediatrics Meta-analysis
Seasonal influenza vaccine effectiveness increased against A(H3N2) and B strains in post-pandemic period Flu vaccine effectiveness shows changes after the COVID-19 pandemic
This meta-analysis of 85 publications analyzed seasonal influenza vaccine effectiveness (VE) comparing pre-pandemic (2010/11-2019/20) and po…
New data reveals that flu vaccines have shown higher effectiveness against certain strains since the COVID-19 pandemic began.
Pregnancy raises influenza susceptibility and severity, with potential fetal neurological effects
Urology Sys. Review
Pregnancy raises influenza susceptibility and severity, with potential fetal neurological effects Pregnancy makes women more likely to get severe flu infections
This systematic review synthesizes evidence on influenza in pregnancy, finding increased susceptibility and severity due to physiological im…
Pregnant people face a higher risk of serious complications from the flu because of natural changes in their immune systems during pregnancy…
Toll-like receptor signaling governs inflammatory phenotypes and progression in infectious myocarditis
Cardiology Sys. Review
Toll-like receptor signaling governs inflammatory phenotypes and progression in infectious myocarditis Toll-like receptors shape severity of infectious myocarditis
This systematic review examines the role of toll-like receptors (TLRs) in infectious myocarditis associated with COVID-19, influenza, and se…
A systematic review finds that pathogen-specific TLR signaling determines inflammation and outcomes in infectious myocarditis, with COVID-19…
Respiratory viral coinfections reshape immune signaling and granuloma stability in Mycobacterium tuberculosis infections
Nephrology Sys. Review
Respiratory viral coinfections reshape immune signaling and granuloma stability in Mycobacterium tuberculosis infections Viral Infections May Change How the Body Fights Tuberculosis
This narrative review synthesizes how respiratory viruses, including SARS-CoV-2 and influenza, impact host immune signaling and granuloma eq…
Research shows that common respiratory viruses like flu or COVID-19 can change how the immune system responds to tuberculosis infections.
Many healthcare students lack knowledge that antibiotics do not speed recovery from colds and flu
Infectious Disease Meta-analysis
Many healthcare students lack knowledge that antibiotics do not speed recovery from colds and flu Healthcare students often lack clear knowledge on antibiotics and viruses
This meta-analysis of 131 studies from 43 countries found that while 88.7% of healthcare students correctly knew antibiotics treat bacterial…
Many healthcare students are unsure if antibiotics can treat common colds or flu, which may lead to improper use of these important medicine…
TCM influenza research surges after 2020, shifting from clinical practice to mechanistic studies
Rheumatology Sys. Review
TCM influenza research surges after 2020, shifting from clinical practice to mechanistic studies Traditional Chinese Medicine Research on Influenza Surges After 2020
A systematic bibliometric analysis of 1,527 publications maps the landscape of Traditional Chinese Medicine (TCM) research on influenza. The…
A review of 1,527 publications shows TCM research for influenza has grown rapidly since 2014, with a sharp rise after 2020. China leads in o…
Synergistic Effects of Prior Influenza and COVID-19 Vaccination on Future Vaccine Uptake
Primary Care & Family Medicine Meta-analysis
Synergistic Effects of Prior Influenza and COVID-19 Vaccination on Future Vaccine Uptake Prior Flu Vaccines May Increase Willingness to Get COVID Shots
Meta-analysis data suggests that prior experience with influenza vaccines significantly boosts patient willingness to receive COVID-19 vacci…
People who have received flu vaccines in the past show a higher willingness and likelihood to get vaccinated against COVID-19.
High-dose quadrivalent influenza vaccine shows non-inferior immunogenicity in Chinese children aged 6 to 35 months
Pediatrics RCT
High-dose quadrivalent influenza vaccine shows non-inferior immunogenicity in Chinese children aged 6 to 35 months High-dose flu shots show greater protection for young children in China
This randomized, double-blind study in 3,000 Chinese children aged 6 to 35 months found an investigational high-dose quadrivalent influenza …
A new study in China shows high-dose flu vaccines work as well as or better than standard shots for toddlers, offering stronger protection a…
mRNA-1010 shows superior efficacy against influenza in older adults
Drug Pipeline RCT
mRNA-1010 shows superior efficacy against influenza in older adults New flu shot cuts illness by 27 percent in adults over 50
A phase 3 trial found mRNA-1010 vaccine had 26.6% relative efficacy versus standard comparator in adults 50+.
A new mRNA flu vaccine reduced confirmed flu illness by 27 percent compared with the standard shot in adults 50 and older.
Six H5N1 vaccine formulations showed immunogenicity and acceptable safety in 420 healthy children aged 6 months to 9 years
Pediatrics RCT
Six H5N1 vaccine formulations showed immunogenicity and acceptable safety in 420 healthy children aged 6 months to 9 years Higher adjuvant content boosts immunity in children without added safety risks
This phase 2, observer-blind, multicenter study evaluated six formulations of MF59-adjuvanted H5N1 vaccine in 420 healthy infants and childr…
A Phase 2 trial in healthy children found that higher adjuvant content improved immune responses to an H5N1 vaccine without increasing side …